FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Related Keywords

Illinois ,United States ,Chicago ,Williamj Gradishar ,Ashling Wahner ,Astrazeneca ,Twitter ,Northwestern University Feinberg School Of Medicine ,Linkedin ,Facebook ,Department Of Medicine ,Live On Air ,Betsy Bramsen Professor ,Breast Oncology ,Northwestern University Feinberg School ,Onclive On Air ,Apple Podcasts ,Google Podcasts ,Amazon Music ,D ,Fda Approval Of Capivasertib Plus Fulvestrant ,Patients With Advanced Hr Positive ,Er2 Negative Breast Cancer Harboring Pik3ca ,Kt1 ,R Pten Alterations ,Capitello 291 Trial ,Nct04305496 ,